Low levels of chromatin modifier zeste homolog 2 (EZH2) expression were detected in PBMCs and CD4+ T-cells from RA patients, which may be attributed to the partial neutralization of EZH2 expression by anti-IL17 antibodies. The gene discussed is CD4; the disease is rheumatoid arthritis.